We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Statin and PAF in Patients With Pacemaker

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00201552
First Posted: September 20, 2005
Last Update Posted: December 9, 2005
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Taiwan University Hospital
  Purpose
Statin could decrease AF burden

Condition Intervention
Paroxysmal Atrial Fibrillation Drug: Statin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Atorvastatin Decreases Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Detailed Description:
Statin could decrease AF burden in patients with PAF.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with pacemaker

Exclusion Criteria:

  • Patients with hepatic dysfunction
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00201552


Contacts
Contact: Chia-Ti Tsai, MD 886-2-23123456 ext 5761 fang31@ms39.hinet.net

Locations
Taiwan
National Taiwan University Hospital Recruiting
Taipei, Taiwan
Contact: Chia-Ti Tsai         
Principal Investigator: Chia-Ti Tsai, MD         
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Study Chair: Jiunn-Lee Lin, MD, PhD National Taiwan University Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00201552     History of Changes
Other Study ID Numbers: 930106
First Submitted: September 12, 2005
First Posted: September 20, 2005
Last Update Posted: December 9, 2005
Last Verified: September 2005

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents